Trials / Not Yet Recruiting
Not Yet RecruitingNCT07268131
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Neoadjuvant TACE Plus Iparomlimab and Tuvonralimab （QL1706）and Adjuvant QL1706 in Resectable BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria: the TITAN-HCC Phase II Trial
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, single-center, prospective trial designed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with ipalimab/tuvonralimab (QL1706) in the peri-operative setting for resectable hepatocellular carcinoma exceeding the Milan criteria, and to explore biomarkers predictive of therapeutic response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | TACE+QL1706 | TACE+QL1706(PD-1/CTLA-4 antibody, 7.5mg/kg, ivgtt, Q3W) |
Timeline
- Start date
- 2025-12-20
- Primary completion
- 2026-10-31
- Completion
- 2029-10-31
- First posted
- 2025-12-05
- Last updated
- 2025-12-22
Source: ClinicalTrials.gov record NCT07268131. Inclusion in this directory is not an endorsement.